SCHEMBL30325908

SCHEMBL30325908

C=C(F)C(=O)Nc1ccc(-c2c(-c3ccc(Oc4nccc(C)n4)cc3)c3c(N)ncc(C#N)c3n2C)c(F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
FGFR1 P11362 1/20 0.48
CYP2C9 P11712 1/20 0.48
FGFR2 P21802 1/20 0.48
FGFR4 P22455 1/20 0.48
FGFR3 P22607 1/20 0.48
CYP2C19 P33261 1/20 0.48
ALOX5AP P20292 2/20 0.35
FEN1 P39748 2/20 0.35
MAP2K1 Q02750 14/20 0.34
RAF1 P04049 12/20 0.34
F10 P00742 1/20 0.32
ABL1 P00519 1/20 0.32
LCK P06239 1/20 0.32
CSF1R P07333 1/20 0.32
LYN P07948 1/20 0.32
KIT P10721 1/20 0.32
SRC P12931 1/20 0.32
FLT1 P17948 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30325690 0.95 CYP3A4 (0.54) CYP3A4CYP2D6FGFR1CYP2C9FGFR2
SCHEMBL30325814 0.94 CYP3A4 (0.46) CYP3A4CYP2D6FGFR1CYP2C9FGFR2
SCHEMBL30325708 0.93 CYP3A4 (0.45) CYP3A4CYP2D6FGFR1CYP2C9FGFR2
SCHEMBL31213844 0.92 CYP3A4 (0.40) CYP3A4CYP2D6FGFR1CYP2C9FGFR2
SCHEMBL30326114 0.92 CYP3A4 (0.39) CYP3A4CYP2D6FGFR1CYP2C9FGFR2
SCHEMBL30325778 0.91 FGFR1 (0.52) CYP3A4CYP2D6FGFR1CYP2C9FGFR2
SCHEMBL28981101 0.91 FGFR1 (0.52) CYP3A4CYP2D6FGFR1CYP2C9FGFR2
SCHEMBL30325864 0.91 FGFR1 (0.44) CYP3A4CYP2D6FGFR1CYP2C9FGFR2
SCHEMBL30325858 0.90 CYP3A4 (0.37) CYP3A4CYP2D6FGFR1CYP2C9FGFR2
SCHEMBL29265844 0.90 CYP3A4 (0.37) CYP3A4CYP2D6FGFR1CYP2C9FGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2024-11-21 US claimed
EP-4405358-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H Pharmaceuticals Co., Ltd. (CN) 2024-07-31 EP claimed
CN-118043327-A FGFR inhibitors and methods of use thereof 思康睿奇(上海)药业有限公司 2024-05-14 CN claimed
WO-2023046117-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2023-03-30 WO claimed
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2024-11-21 US disclosed
EP-4405358-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H Pharmaceuticals Co., Ltd. (CN) 2024-07-31 EP disclosed
CN-118043327-A FGFR inhibitors and methods of use thereof 思康睿奇(上海)药业有限公司 2024-05-14 CN disclosed
WO-2023046117-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2023-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF FGFR1, FGFR3, FGFR4 CYP3A4 594/4885CYP2D6 638/4885FGFR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.